DBV TECHNOLOGIE/S (DBVT) Upgraded at BidaskClub

DBV TECHNOLOGIE/S (NASDAQ:DBVT) was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating in a report released on Friday.

Several other analysts have also recently weighed in on the company. Zacks Investment Research cut DBV TECHNOLOGIE/S from a “hold” rating to a “sell” rating in a report on Wednesday. Bank of America dropped their price target on DBV TECHNOLOGIE/S from $33.00 to $30.00 and set a “buy” rating for the company in a report on Friday, November 2nd. Stifel Nicolaus assumed coverage on DBV TECHNOLOGIE/S in a research note on Thursday, September 13th. They set a “buy” rating and a $35.00 price objective on the stock. Morgan Stanley lowered their price objective on DBV TECHNOLOGIE/S from $28.00 to $27.00 and set an “equal weight” rating on the stock in a research note on Tuesday, September 11th. Finally, ValuEngine upgraded DBV TECHNOLOGIE/S from a “sell” rating to a “hold” rating in a research note on Thursday, August 2nd. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company’s stock. DBV TECHNOLOGIE/S has a consensus rating of “Buy” and an average target price of $33.67.

NASDAQ:DBVT opened at $20.00 on Friday. DBV TECHNOLOGIE/S has a 1-year low of $16.65 and a 1-year high of $26.98.

Institutional investors have recently bought and sold shares of the business. Exane Asset Management increased its stake in DBV TECHNOLOGIE/S by 17.9% during the 2nd quarter. Exane Asset Management now owns 50,000 shares of the company’s stock worth $964,000 after acquiring an additional 7,600 shares during the period. Boxer Capital LLC increased its stake in DBV TECHNOLOGIE/S by 4.4% during the 2nd quarter. Boxer Capital LLC now owns 1,065,000 shares of the company’s stock worth $20,544,000 after acquiring an additional 45,000 shares during the period. Dynamic Technology Lab Private Ltd bought a new position in DBV TECHNOLOGIE/S during the 2nd quarter worth $285,000. Jennison Associates LLC increased its stake in DBV TECHNOLOGIE/S by 17.0% during the 2nd quarter. Jennison Associates LLC now owns 1,707,732 shares of the company’s stock worth $32,942,000 after acquiring an additional 247,523 shares during the period. Finally, First Midwest Bank Trust Division increased its stake in DBV TECHNOLOGIE/S by 19.3% during the 3rd quarter. First Midwest Bank Trust Division now owns 163,358 shares of the company’s stock worth $3,669,000 after acquiring an additional 26,372 shares during the period. Hedge funds and other institutional investors own 44.65% of the company’s stock.

About DBV TECHNOLOGIE/S

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.

Further Reading: Understanding Market Liquidity

Analyst Recommendations for DBV TECHNOLOGIE/S (NASDAQ:DBVT)

Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply